

CLAIMS

What is claimed is:

1. A method of screening *in vivo* for a condition requiring or associated with angiogenesis, comprising the steps of:
 - (a) administering to a warm-blooded animal in a diagnostically effective amount any one of compounds 1-15 of Figure 1; and
 - (b) detecting the compound in the animal.
2. The method of claim 1 wherein the compound possesses a detectable component.
3. The method of claim 2 wherein the detectable component is a radioisotope.
4. A method of screening *in vitro* for a condition requiring or associated with angiogenesis, comprising the steps of:
 - (a) contacting a biological preparation with a diagnostically effective amount of any one of compounds 1-15 of Figure 1; and
 - (b) detecting the compound in the preparation.
5. The method of claim 4 wherein the compound possesses a detectable component.
6. The method of claim 5 wherein the detectable component is a fluorescent group.

7. The method of claim 6 wherein the fluorescent group is detected by fluorescence activated cell sorting.

8. A method for *in vitro* identification of cells expressing E-selectin, comprising the steps of:

- (a) contacting a biological preparation with any one of compounds 1-15 of Figure 1; and
- (b) detecting the compound in the preparation.

9. The method of claim 8 wherein the compound possesses a detectable component.

10. The method of claim 9 wherein the detectable component is a fluorescent group.

11. The method of claim 10 wherein the fluorescent group is detected by fluorescence activated cell sorting.

12. A method of treating a condition requiring or associated with angiogenesis, comprising the step of administering to a warm-blooded animal in a therapeutically effective amount any one of compounds 1-15 of Figure 1.

13. The method of claim 12 wherein the compound possesses a therapeutic agent.

14. The method of claim 13 wherein the therapeutic agent inhibits angiogenesis.

15. The method of claim 13 wherein the therapeutic agent promotes angiogenesis.

16. A method for promoting angiogenesis in tissue engineering, comprising the step of contacting cells with any one of compounds 1-15 of Figure 1, wherein the compound possesses an angiogenesis promoting agent.

17. A conjugate comprising any one of compounds 1-15 of Figure 1 covalently attached to a diagnostic or therapeutic agent.

18. The conjugate of claim 17 wherein the therapeutic agent is an antineoplastic agent.

19. The conjugate of claim 17 wherein the therapeutic agent is an angiogenesis promoting agent.

20. The conjugate of claim 17 wherein the therapeutic agent is an angiogenesis inhibiting agent.